Last update July 2, 2022
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
7-Chloro-1,5-dihydro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4(3H)-dione belongs to this group or family:
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Long-acting benzodiazepine indicated in It is used in the treatment of epilepsy and anxiety disorders. Oral administration once a day.
According to an study from 1978, it is excreted in breastmilk in small amounts, but which could be significant. (Schaefer 2007 p728, Bennett 1996 p 409)
A 25-day-old infant whose mother was taking clobazam and levetiracetam presented sedation, vomiting and weight loss (Paret 2014). No adverse effects were reported in a newborn whose mother was taking tiagabine, clobazam and oxcarbazepine daily. (Tomson 2007)
It is advisable to monitor drowsiness and the adequate feeding of the infant during maternal treatment with clobazam. (Bar-Oz 2012)
In general, occasional and low dose use of benzodiazepines is compatible with breastfeeding. (Kelly 2012, Rubin 2004, Iqbal 2002, Hägg 2000, McElhatton 1994, Lee 1993, Bennet 1996, Kanto 1982)
It is advisable to choose short-acting benzodiazepines and use the minimum effective dose (Rowe 2013), especially during the neonatal period and in cases of prematurity because they can accumulate in the infant during chronic use. (Sachs 2013)
It is advisable to monitor drowsiness and the adequate feeding of the infant. It is not recommended to share a bed with the baby if this medication is being taken due to an increased risk of suffocation or sudden infant death. (ABM 2020, UNICEF 2018, 2017, 2014 and 2013, Landa 2012, ABM 2008, UNICEF 2006)
See below the information of this related product: